DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation

DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation

Non-small cell lung cancer (NSCLC) patients treated with small molecule EGFR inhibitors, such as gefitinib, frequently develop drug resistance due to the presence of secondary mutations like the T790M mutation on EGFR exon 20. These mutations may originate from small subclonal populations in the pri...

Full description

Bibliographic Details
Main Authors:	Guha, Minakshi, Castellanos-Rizaldos, Elena, Makrigiorgos, G. Mike
Format:	Online
Language:	English
Published:	Public Library of Science 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689726/

Similar Items

EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method
by: Watanabe, Kana, et al.
Published: (2016)

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
by: Kim, Hye-Ryoun, et al.
Published: (2013)

Differential strand separation at critical temperature: A minimally disruptive enrichment method for low-abundance unknown DNA mutations
by: Guha, Minakshi, et al.
Published: (2013)

Enrichment of Mutations in Multiple DNA Sequences Using COLD-PCR in Emulsion
by: Castellanos-Rizaldos, Elena, et al.
Published: (2012)

Novel Methodology for Rapid Detection of KRAS Mutation Using PNA-LNA Mediated Loop-Mediated Isothermal Amplification
by: Itonaga, Masahiro, et al.
Published: (2016)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
by: Yamada, Teppei, et al.
Published: (2013)

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
by: Francesco Passiglia, et al.
Published: (2018-09-01)

Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
by: Berz, David, et al.
Published: (2016)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
by: Matsuo, Norikazu, et al.
Published: (2016)

Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment
by: Lee, Hyun Ju, et al.
Published: (2013)

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
by: Li, Hang, et al.
Published: (2014)

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
by: Yamane, Hiromichi, et al.
Published: (2013)

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
by: Zhang, Shirong, et al.
Published: (2015)

Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR
by: Iwama, Eiji, et al.
Published: (2015)

Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors
by: C., George Priya Doss, et al.
Published: (2014)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
by: Wang, Shuhang, et al.
Published: (2016)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
by: Zhao, Ren, et al.
Published: (2016)

Disruption of Higher Order DNA Structures in Friedreich’s Ataxia (GAA)n Repeats by PNA or LNA Targeting
by: Bergquist, Helen, et al.
Published: (2016)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
by: WANG, CHENGDE, et al.
Published: (2015)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
by: Sasada, Tetsuro, et al.
Published: (2013)

Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
by: Sakai, Asao, et al.
Published: (2013)

Erratum to: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer
by: Han, Ji-Youn, et al.
Published: (2016)

PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer
by: Han, Ji-Youn, et al.
Published: (2016)

COLD-PCR Amplification of Bisulfite-Converted DNA Allows the Enrichment and Sequencing of Rare Un-Methylated Genomic Regions
by: Castellanos-Rizaldos, Elena, et al.
Published: (2014)

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
by: Lee, Youngjoo, et al.
Published: (2016)

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
by: Regales, Lucia, et al.
Published: (2007)

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
by: Xiang, Mingli, et al.
Published: (2013)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Lai, Wei-Yun, et al.
Published: (2014)

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer
by: Li, Hongde, et al.
Published: (2016)

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
by: Carter, Corey A., et al.
Published: (2016)

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
by: Sueoka‐Aragane, Naoko, et al.
Published: (2016)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
by: OFUJI, KAZUYA, et al.
Published: (2014)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
by: Jia, Yong, et al.
Published: (2016)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01)

The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer
by: Bemanian, Vahid, et al.
Published: (2015)

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
by: Xu, Wei, et al.
Published: (2015)

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
by: Wang, Shuhang, et al.
Published: (2016)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
by: Thress, Kenneth S., et al.
Published: (2015)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
by: Wu, Hong, et al.
Published: (2015)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
by: Zheng, D., et al.
Published: (2016)